Nanoparticles for protein drug delivery
View Patent ↗The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one protein drug or bioactive agent characterized with a positive surface charge and their enhanced permeability for paracellular protein drug and bioactive agent delivery.
1. A bioactive agent delivery system for enhancing the epithelial permeation of at least one bioactive agent, comprising nanoparticles or collapsed nanoparticles, said nanoparticles or said collapsed nanoparticles comprising an outer portion that is dominated by positively charged chitosan, an inner portion that contains negatively charged substrate, wherein said substrate is PGA, wherein said negatively charged substrate is at least partially reacted with a portion of said positively charged chitosan in the inner portion, and said at least one bioactive agent loaded within said nanoparticles or said collapsed nanoparticles.
2. The bioactive agent delivery system of claim 1 , wherein said bioactive agent is insulin or insulin analog.
3. The bioactive agent delivery system of claim 1 , wherein said PGA is γ-PGA, α-PGA, derivatives of PGA or salts of PGA.
4. The bioactive agent delivery system of claim 1 , wherein said nanoparticles are formed via a simple and mild ionic-gelation method.
5. The bioactive agent delivery system of claim 1 , wherein a surface of said collapsed nanoparticles is characterized with a positive surface charge.
6. The bioactive agent delivery system of claim 1 , wherein said nanoparticles or said collapsed nanoparticles further comprise magnesium sulfate or sodium tripolyphosphate (TPP).
7. The bioactive agent delivery system of claim 1 , wherein said nanoparticles have a mean particle size between about 50 and 400 nanometers.
8. The bioactive agent delivery system of claim 1 , wherein said collapsed nanoparticles have a mean size between about 10 and 100 nanometers.
9. The bioactive agent delivery system of claim 1 , wherein at least a portion of said outer portion of said nanoparticles is crosslinked.
10. The bioactive agent delivery system of claim 1 , wherein said chitosan has a molecular weight about 80 kDa or less.
11. The bioactive agent delivery system of claim 1 , wherein said chitosan is N-trimethyl chitosan.
12. The bioactive agent delivery system of claim 1 , wherein said bioactive agent comprises anti-inflammatory drugs.
13. The bioactive agent delivery system of claim 1 , wherein said bioactive agent comprises anti-epileptic drugs.
14. The bioactive agent delivery system of claim 1 , wherein said bioactive agent is Alzheimer's antagonist.
15. The bioactive agent delivery system of claim 1 , wherein said bioactive agent comprises anti-HIV drugs.
16. The bioactive agent delivery system of claim 1 , wherein said nanoparticles or said collapsed nanoparticles are freeze-dried.
17. The bioactive agent delivery system of claim 2 , wherein said bioactive agent is insulin lispro (Humalog) having a chemical formula C 257 H 383 N 65 O 77 S 6 , insulin having a chemical formula C 254 H 377 N 65 O 75 S 6 , or insulin having a chemical formula C 267 H 404 N 72 O 78 S 6 .
18. The bioactive agent delivery system of claim 2 , wherein said bioactive agent is insulin glargine (Lantus) having a chemical formula C 267 H 408 N 72 O 77 S 6 insulin aspart (Novolog) having a chemical formula C 256 H 381 N 65 O 79 S 6 , or insulin detemir having a chemical formula C 267 H 402 N 64 O 76 S 6 .
19. The bioactive agent delivery system of claim 1 , wherein said bioactive agent comprises glucagon or glucagon-like peptide-1.
20. The bioactive agent delivery system of claim 1 , wherein said bioactive agent comprises growth hormone, erythropoietins, or interferons.